Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
57 results about "Isocitrate Dehydrogenase-I" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Isocitrate dehydrogenase (IDH) (EC 1.1.1.42) and (EC 1.1.1.41) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2.
Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
Owner:FORMA THERAPEUTICS INC
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
ActiveUS20160083366A1Easy to optimizeBiocideOrganic chemistryIsocitrate Dehydrogenase-ILimonoate dehydrogenase
The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
Owner:FORMA THERAPEUTICS INC
Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
Owner:FORMA THERAPEUTICS INC
Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
Owner:FORMA THERAPEUTICS INC
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
ActiveUS10005734B2Organic active ingredientsNervous disorderIsocitrate Dehydrogenase (NAD+)Isocitrate Dehydrogenase-I
The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:where A, B, W1, W2, W3, and R1-R8 are described herein.
Owner:FORMA THERAPEUTICS INC
Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:where A, B, W1, W2, W3, and R1-R6 are described herein.
Owner:FORMA THERAPEUTICS INC
Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Fluorescent PCR (Polymerase Chain Reaction) detection kit for IDH1/IDH2 (isocitrate dehydrogenase 1/isocitrate dehydrogenase 2) gene mutation and application thereof
InactiveCN103436613AStrong specificityEnrichmentMicrobiological testing/measurementDNA/RNA fragmentationNucleotideBlood plasma
The invention relates to a fluorescent PCR detection kit for the IDH1 / IDH2 (isocitrate dehydrogenase 1 / isocitrate dehydrogenase 2) gene mutation and application thereof, and particularly provides a nucleotide sequence used for detecting the IDH1 / IDH2 gene mutation, a kit with the nucleotide sequence and the application of the kit to detection of the IDH1 / IDH2 gene mutation. The nucleotide sequence comprises a specific ARMS (Amplification Refractory Mutation System) primer, a general mutation detection TaqMan probe and a nucleic acid amplification retardation primer. The kit can be used for quickly detecting the IDH1 / IDH2 gene mutation with high throughput and at a low cost, is high in sensitivity, good in specificity, low in pollution and quick and safe to operate, can be suitable for high-sensitivity detection of trace mutation in general clinic samples such as fresh frozen tissues and paraffin tissues, especially non-traumatic serums or plasma samples in addition to pathological tissues.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
RNA interference mediated inhibition of isocitrate dehydrogenase (IDH1) gene expression
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of IDH1 and mutant IDH1 gene expression and / or activity, and / or modulate an IDH1 or mutant IDH1 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules, including small nucleic acid molecules such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules, that are capable of mediating or that mediate RNA interference (RNAi) against IDH1 or mutant IDH1 gene expression.
Owner:SIRNA THERAPEUTICS INC
Construction and applications of corynebacterium glutamicum mutant strain for producing L-homoserine
The invention discloses construction and applications of a corynebacterium glutamicum mutant strain for producing L-homoserine, and belongs to the technical field of fermentation engineering. Corynebacterium glutamicum ATCC 13032 is taken as a starting strain to knock out regulatory protein McbR, homoserine kinase, transport protein MetD, phosphoenolpyruvate carboxykinase; the expression of isocitrate dehydrogenase is down regulated; transport protein BrnFE, aspartic semialdehyde dehydrogenase and homoserine dehydrogenase are overexpressed; and the expression of aspartate kinase, pyruvate carboxylase and the aspartate kinase I derived from escherichia coli are enhanced. Shake flask culture can be performed on the mutant strain for 48 h, and the yield of L-homoserine can reach 8.8 g / L.
Owner:JIANGNAN UNIV
Cold-resistant gene engineering application method of rice OsICE2 gene
InactiveCN103290050AReduce expressionIncrease increaseFermentationGenetic engineeringBiotechnologyGenetically modified rice
The invention discloses a cold-resistant gene engineering application method of rice OsICE2 gene. The method includes: (1) gene cloning, (2) vector construction, (3) transgenosis, (4) analysis of the cold-resistant phenotype of OsICE2 by a transgenic technology, and (5) comparative analysis of a transgenic plant and a control plant in the cold-resistant physiological aspect. By the steps, the method determines the influence of OsICE2 gene on protein expression quantity under low temperature stress, and finds that a transgenic rice strain can slow down the reduction of protein expression quantity of RuBi sCO subunit binding-protein alpha subunit, RuBi sCO activase small isoform precursor, Chlorophyll a-b binding protein and isocitrate dehydrogenase under low temperature stress, and improves the expression increase range of 70 kDa heat shock-related protein.
Owner:HUAIYIN TEACHERS COLLEGE
Corynebacterium glutamicum capable of increasing lysine yield and constructing method of corynebacterium glutamicum
InactiveCN108441525AAchieve balanceBacteriaMicroorganism based processesSphaerotrichia divaricataStreptococcus mutans
The invention discloses corynebacterium glutamicum capable of increasing lysine yield and a constructing method of the corynebacterium glutamicum, and belongs to the technical field of genetic engineering. A genetic engineering method is adopted for substituting IDH (isocitrate dehydrogenase) coding gene icdCg in corynebacterium glutamicum RG for IDH coding gene icdSm in streptococcus mutans, andaccordingly, affinity of IDH to different redox cofactors is regulated, the problem of intracellular redox imbalance in the synthesis process of L-lysine is solved, and the L-lysine accumulation capacity of the strain is improved. Tank (5L fermentation tank) experiments show that L-lysine accumulation amount of the recombinant bacterium reaches 121.4 g / L. Redox cofactor affinity of IDH in corynebacterium glutamicum is successfully changed, problem of intracellular redox imbalance during synthesis of L-lysine is solved, and a new idea for breeding the L-Lysine high-yield strain is provided.
Owner:JIANGNAN UNIV
Double-aryl maleimide compound, pharmaceutically acceptable salt thereof, method for preparing double-aryl maleimide compound and pharmaceutically acceptable salt and application of double-aryl maleimide compound and pharmaceutically acceptable salt
The invention discloses a double-aryl maleimide compound, pharmaceutically acceptable salt thereof, a method for preparing the double-aryl maleimide compound and the pharmaceutically acceptable salt and application of the double-aryl maleimide compound and the pharmaceutically acceptable salt. The double-aryl maleimide compound and the pharmaceutically acceptable salt can be particularly used as isocitrate dehydrogenase 1 (IDH1) mutant inhibitors and can be applied to treating malignant tumor such as glioma and acute myeloid leukemia. The double-aryl maleimide compound, the pharmaceutically acceptable salt, the method and the application have the advantages that the double-aryl maleimide compound has efficiently selective IDH1 mutant inhibitory activity, and accordingly the double-aryl maleimide compound and the pharmaceutically acceptable salt can be used for treating the IDH1 mutant mediated malignant tumor such as the glioma and the acute myeloid leukemia; the double-aryl maleimide compound, the pharmaceutically acceptable salt and the method are reasonable in design, and the method is simple and practical.
Owner:ZHEJIANG UNIV OF TECH +1
Steroidal compounds as well as extraction method and application thereof
ActiveCN108440471AEnhanced inhibitory effectOrganic active ingredientsSteroidsIsocitrate dehydrogenasePhotochemistry
The invention belongs to the technical field of medicines, and discloses an extraction method for steroidal components in glossy ganoderma and an application of the steroidal components. The compoundshave structures represented by a formula (I) and a formula (II) shown in the description. The compounds and compositions of the compounds disclosed by the invention have an inhibitory effect on glycolysis first rate-limiting enzyme HK-2 or isocitrate dehydrogenase (IDH1), thereby having a significant anti-tumor effect; and the compounds have good research and development prospects.
Owner:SHENYANG PHARMA UNIVERSITY
IDH1 and IDH2 mutations in cholangiocarcinoma
InactiveUS20130123335A1Aid in prognosis and selectionMicrobiological testing/measurementFermentationMammalIDH2
This document relates to methods and materials involved in assessing isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) mutations in a mammal (e.g., human). For example, this document provides methods and materials for diagnosis, characterization, determining prognosis, and treatment of cholangiocarcinoma tumor in a mammal.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Compounds and methods for the treatment of isocitrate dehydrogenase related diseases
The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:
Owner:THE BROAD INST INC +1
Method for synthesizing glyoxylic acid by utilizing corynebacterium glutamicum based on CRISPRi regulation
ActiveCN113136382AGrowth is not affectedBlocking tributary metabolic pathwaysMicroorganism based processesFermentationIsocitrate Dehydrogenase (NAD+)Gene expression level
The invention provides a method for synthesizing glyoxylic acid by utilizing corynebacterium glutamicum based on CRISPRi (clustered regularly interspaced short palindromic repeats i) regulation. According to the method, an acetaldehyde dehydrogenase coding gene of the corynebacterium glutamicum is replaced through a dCas9 expression cassette gene; a lactic dehydrogenase encoding gene of corynebacterium glutamicum is replaced by sgRNA transcription units of an isocitrate dehydrogenase encoding gene and a malic acid synthetase encoding gene, an isocitrate lyase encoding gene of the corynebacterium glutamicum is over-expressed to obtain a corynebacterium glutamicum engineering strain, and the engineering strain is cultured to ferment and synthesize glyoxylic acid. Corynebacterium glutamicum is used as a starting strain, a lactic dehydrogenase coding gene and an acetaldehyde dehydrogenase coding gene which are key enzymes of branch metabolism of the corynebacterium glutamicum are knocked out, a CRISPRi regulation system is established, expression levels of an isocitrate dehydrogenase coding gene and a malic acid synthase coding gene are reduced, and meanwhile, an isocitrate lyase coding gene is overexpressed, so that a method for biosynthesizing glyoxylic acid by using corynebacterium glutamicum is established.
Owner:HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY
Primers, reagent kit and method for detecting IDH1 (isocitrate dehydrogenase 1) R132H gene variation by aid of ddPCR (droplet digital polymerase chain reaction) technologies
InactiveCN108384857AImproved prognosisStrong specificityMicrobiological testing/measurementDNA/RNA fragmentationIDH1Small fragment
The invention discloses primers, a reagent kit and a method for detecting IDH1 (isocitrate dehydrogenase 1) R132H gene variation by the aid of ddPCR (droplet digital polymerase chain reaction) technologies. The method includes extracting cfDNA (cell-free deoxyribonucleic acid) in peripheral blood; designing two probes and a pair of primers for IDH1R132H mutant types and wild types; carrying out ddPCR amplification by the aid of the cfDNA used as a template; carrying out data analysis on obtained amplification products to obtain absolute quantities and proportions of IDH1R132H mutant genes. Thereagent kit for detecting the IDH1R132H gene variation is based on the method. The primers, the reagent kit and the method have the advantages that provided primer amplification fragments 83bp are particularly applicable to amplifying small-fragment DNA samples such as plasma free DNA and can be combined with the detection probes, accordingly, the IDH1R132H gene variation with extremely low abundance can be detected from the cfDNA, the primers, the reagent kit and the method are good in specificity and high in sensitivity, human IDH1R132H gene variation can be absolutely quantitatively detected by the aid of the primers, the reagent kit and the method, and important effects can be realized by the primers, the reagent kit and the method for guiding clinical treatment and improving patientprognosis; the IDH1R132H gene variation can be detected only by the aid of the peripheral blood without tissue specimen collection, and accordingly the method is particularly suitable for patients intolerant to tissue sampling.
Owner:PRIMBIO GENES BIOTECH WUHAN CO LTD
Genetically engineered bacterium for producing hydroxyectoine and application of genetically engineered bacterium
ActiveCN112877270AEfficient synthesisWeaken Competitive Inhibition PathwayBacteriaMicroorganism based processesBiotechnologyGlutaric acid
The invention belongs to the technical field of gene engineering, and particularly relates to the construction and the application of a gene engineering bacterium for producing hydroxyectoine. According to the invention, key genes in a hydroxyectoine synthesis route are strengthened on the genome, a hydroxyectoine competitive inhibition route is weakened, the hydroxyectoine synthesis route is constructed, and an isocitrate dehydrogenase coding gene icd is over-expressed to increase the supply of a precursor alpha-ketoglutaric acid. Meanwhile, supply of a precursor substance alpha-ketoglutaric acid is dynamically adjusted and controlled through an esaI / esaR quorum sensing circuit strategy, metabolism of the alpha-ketoglutaric acid in tricarboxylic acid circulation is automatically adjusted according to the cell density, and the hydroxyectoine high-yield strain is obtained. The constructed strain can realize efficient synthesis of hydroxyectoine under the fermentation condition that alpha-ketoglutaric acid is not added, does not accumulate a byproduct ectoine, and has important industrial application value.
Owner:TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY
Compounds and methods for the treatment of isocitrate dehydrogenase related diseases
The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:
Owner:THE BROAD INST INC +1
Isocitrate dehydrogenase, gene thereof, and use of the same in the treatment of obesity, hyperlipidemia, and fatty liver in lipid biosynthesis
The present invention relates to a cytosolic isocitrate dehydrogenase, its gene, and its use in the treatment of obesity, hyperlipidemia, and fatty liver. The expression of the IDPc gene and the concomitant increase in IDPc level bring about an increase in the cellular level of NADPH, which causes the lipid deposition in adipocytes, leading to obesity and fatty liver. A decrease in the cellular level of NADPH, resulting from the suppression of the gene expression of IDPc, has the effect of inhibiting the lipid deposition in adipocytes. Further, by taking advantage of the suppressive or inhibitory effects of isocitrate dehydrogenase inhibitors, pharmaceutically effective materials for the prophylaxis and treatment of obesity, hyperlipidemia and fatty liver can be developed.
Owner:TG LIFE IND +1
IDH gene dsRNA capable of improving termite control effect of metarhizium anisopliae
ActiveCN111849984AStrong specificityReduced resistance to Metarhizium anisopliae infectionBiocideAnimal repellantsBiotechnologyIsocitrate Dehydrogenase (NAD+)
The invention relates to IDH gene dsRNA capable of improving the termite control effect of metarhizium anisopliae. The sequence design of the dsRNA is derived from a key metabolic enzyme gene, namelyan isocitrate dehydrogenase (IDH) gene, in bodies of the eupolyphaga nigromaculata and the termites nigromaculata. An IDH dsRNA template is synthesized by utilizing a specific primer of the IDH gene,and then dsIDH is generated through transcription of a T7 in-vitro transcription system. After dsIDH is introduced into a termite body by adopting an RNAi technology, the IDH gene expression is reduced, the antifungal activity of the termite is remarkably reduced, the apoptosis rate is increased, the infection level is increased, the IDH activity is reduced, the ATP level is reduced, the movementdistance is reduced, and the death rate of the termite is remarkably increased. The dsIDH can significantly improve the control effect of metarhizium anisopliae on termites, is environmentally friendly and safe to people and livestock, and has good research and application prospects.
Owner:宜昌市金通白蚁防治有限公司 +1
Enzyme activity detection kit for alpha-oxoglutarate dependent enzyme and application thereof
PendingCN109929908AMicrobiological testing/measurementIsocitrate Dehydrogenase (NAD+)Mutated protein
The invention discloses an enzyme activity detection kit for alpha-oxoglutarate dependent enzyme and an application thereof. The kit includes one of reduced coenzyme II (NADPH) or reduced coenzyme I (NADH), an isocitrate dehydrogenase IDH mutant protein and buffer salt, and the IDH mutant protein refers to an IDH mutant protein having a novel function of catalyzing alpha-oxoglutarate (2-OG) obtained after mutation of a specific amino acid of IDH. As a preferred scheme, the kit further includes a metal ion that competes for ferrous ions. The invention provides a method for detecting the contentof the alpha-oxoglutarate with high efficiency and high precision, which can be used for detecting the enzymatic activity of alpha-oxoglutarate dependent enzyme, determining the enzyme kinetic parameters, and performing high-throughput drug screening by targeting the type of enzyme. The method solves the problems of complex operation, low accuracy, reproducibility, low flux, and difficulty in screening high-throughput drugs for the enzyme activity detection of the alpha-oxoglutarate dependent enzyme.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Sultam Compound And Application Method Thereof
ActiveUS20210047314A1Strong inhibitory activityImprove the level ofOrganic active ingredientsOrganic chemistryIsocitrate Dehydrogenase-IPharmaceutical medicine
Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD +2
Isoxazole derivative as mutated isocitrate dehydrogenase 1 inhibitor
ActiveCN106795146AStrong activity inhibitionInhibitionOrganic active ingredientsOrganic chemistryIDH1Limonoate dehydrogenase
It was discovered that a compound of general formula (I) that has an isoxazole skeleton has an excellent inhibitory activity on a mutated IDH1 protein, inhibits 2-HG production by the aforesaid protein and can effectively inhibit the proliferation of various tumors expressing the aforesaid protein. In general formula (I), R1, R2, R3, Y and Z are each as defined in claim 1.
Owner:DAIICHI SANKYO CO LTD +1
Quick detection method for IDH2 gene mutation
ActiveCN102925579ATime consumingIncrease costMicrobiological testing/measurementIsocitrate Dehydrogenase-IMicrobiology
The invention provides a quick detection method for IDH2 (isocitrate dehydrogenase) gene mutation, which comprises the following steps that a pair of wild type primers is designed at the two ends of an IDH2 gene mutational site; a pair of mutational type primers is designed at the mutational site; the wild type primers and the mutational type primers of an IDH2 gene are designed respectively; the primers are amplified to be a corresponding wild type template and a mutational type template respectively; the two templates are subjected to PCR (polymerase chain reaction) amplification by the wild type primers to be a corresponding wild type target fragment and a mutational type target fragment respectively; the two fragments are mixed in different proportions; and an HRM (high resolution melting) method is adopted to for distinguishing. Compared with other methods, the quick detection method has the advantages of high specificity, high sensitivity, convenience and quickness, and is higher in flux and lower in single cost.
Owner:上海赛安医学检验所有限公司
Application of isocitrate dehydrogenase in improvement of formaldehyde absorption and metabolism capability of plants
ActiveCN113502276AImprove absorption efficiencyEasy to storeOxidoreductasesFermentationNicotiana tabacumNucleotide
The invention discloses an application of an arabidopsis thaliana isocitrate dehydrogenase gene AtIDH3 in improvement of formaldehyde absorption and metabolism capability of a plant. The nucleotide sequence of the arabidopsis thaliana isocitrate dehydrogenase gene AtIDH3 is as shown in SEQ ID NO:1. The AtIDH3 gene is recombined into a plant expression vector, wild tobacco is transformed, and AtIDH3 transgenic tobacco is obtained through screening; experimental results show that under the same concentration stress and the same time, the formaldehyde absorption effect of the overexpressed tobacco is better than that of the wild tobacco; under the stress of liquid formaldehyde, the expression quantity of AtIDH3 transcriptional level of wild tobacco and 14-3-3c overexpressed tobacco is obviously increased. Yeast double hybrid, Pull-down and Co-IP experiments prove that the 14-3-3c protein interacts with the AtIDH3, and the result shows that the over-expressed transgenic tobacco has higher formaldehyde absorption capacity than wild tobacco.
Owner:KUNMING UNIV OF SCI & TECH
A kind of L-carnitine-producing Escherichia coli genetically engineered bacteria and its construction method and application
ActiveCN104928225BHigh copy numberEnhance and stabilize expressionBacteriaMicroorganism based processesBiotechnologyIsocitrate Dehydrogenase (NAD+)
Owner:武汉中科光谷绿色生物技术有限公司
Sultam compound and application method thereof
ActiveUS11111240B2Strong inhibitory activityImprove the level ofOrganic active ingredientsOrganic chemistryIsocitrate Dehydrogenase-IPharmaceutical medicine
Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD +2
Isoxazole derivatives as mutant isocitrate dehydrogenase 1 inhibitors
ActiveCN106795146BInhibitionStrong activity inhibitionOrganic active ingredientsOrganic chemistryIDH1Isocitrate Dehydrogenase (NAD+)
Owner:DAIICHI SANKYO CO LTD +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com